Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06795412 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumours, sponsored by Pyxis Oncology.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 220
- Enrollment target
- 15
- Study locations
NCT06795412 is a Phase 1 study of Advanced Solid Tumours that is actively recruiting participants, run by Pyxis Oncology. The registered enrollment target is 220 participants, above the 187-participant average among 3 other Advanced Solid Tumours trials with a reported enrollment target (18% higher). The trial reports 15 study locations across 9 states.
The verdict
NCT06795412, a Phase 1 study of Advanced Solid Tumours, is actively recruiting participants, sponsored by Pyxis Oncology.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 220 participants
- Enrollment target
- 15
- Study locations
Study Summary
The primary objective of this study is to determine the recommended Phase 2 doses (RP2D(s)) and maximum tolerated dose (MTD) of PYX-201 in combination with pembrolizumab for participants with advanced solid tumors.
Conditions Studied
Interventions
- DRUG pembrolizumab
- DRUG PYX-201
Study Locations (15)
Madrid
- Hospital Universitario Ramón y Cajal - Madrid
- START Madrid - Hospital Universitario Fundación Jiménez Díaz - Madrid
- Hospital Universitario 12 de Octubre - Madrid
California
- University of California San Diego - San Diego
- Sarcoma Oncology Center - Santa Monica
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Pennsylvania
- University of Pennsylvania - Philadelphia
- University of Pittsburgh Medical Center - Pittsburgh
Texas
- University of Texas - M.D. Anderson Cancer Center - Houston
- NEXT Oncology Houston - Houston
Florida
- Moffitt Cancer Center - Tampa
Virginia
- NEXT Virginia - Fairfax
Barcelona
- Hospital Universitario Vall d'Hebron - Barcelona
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2025-04-15 |
| Est. Completion | 2027-12-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06795412
The ClinicalTrials.gov registry entry for NCT06795412 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 187-participant average among 3 other Advanced Solid Tumours trials with a reported enrollment target (18% higher). The listed sponsor is Pyxis Oncology, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Tumours appearing as the primary indexed condition, and to 2 interventions - of which pembrolizumab is the first listed.
NCT06795412 reports 15 study locations spanning 9 distinct geographic areas - top geographies include Madrid, California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06795412 about?
NCT06795412 is a clinical study titled "Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors". The primary objective of this study is to determine the recommended Phase 2 doses (RP2D(s)) and maximum tolerated dose (MTD) of PYX-201 in combination with pembrolizumab for participants with advanced solid tumors.
What is the current status of trial NCT06795412?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 220 participants. The study started on 2025-04-15. Estimated completion is 2027-12-06.
What conditions does trial NCT06795412 study?
This clinical trial studies the following conditions: Advanced Solid Tumours.
What interventions are being tested in trial NCT06795412?
The interventions under investigation include: pembrolizumab (DRUG), PYX-201 (DRUG).
Who is sponsoring clinical trial NCT06795412?
This trial is sponsored by Pyxis Oncology, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06795412 being conducted?
This trial has 15 study locations across California, Florida, Massachusetts, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumours
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.